Claudine SapèdeDirector, Global HTA Policy at Novartis International
Claudine Sapède is Director, Global HTA Policy at Novartis in Global Public Affairs based in Basel, Switzerland. In this role, she focuses on value assessment, HTA and reimbursement decision-making approaches as well as their impact on patient access to innovative treatments. She engages with internal and external stakeholders involved in setting or shaping HTA, pricing and reimbursement decisions.
Claudine is currently a member and active contributor of the EFPIA’s market access and HTA working groups and co-lead one of the workstream related to the implementation of the EU HTA regulation.
Prior to this role, she has had a range of different roles in the field of pricing and market access both at country and global levels in consulting as well as large multinational pharma organizations. Her business career in the pharmaceutical sector over 20 years spans the full spectrum of evidence generation, value demonstration, market access strategies, pricing, and policy.
HTA procedures in the European Union are being harmonized – the industry’s view., 09:30View Session